Clinical Trial

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Protocol Amendment History 48 amendments
This ClinicalTrials.gov record has been amended 48 times since 2020-11-30; most recent amendment 2026-03-03.
Status change: Recruiting → Active, Not Recruiting 2023-06-30
Status change: Not Yet Recruiting → Recruiting 2021-01-28
Trial Details
NCT Number NCT04656652
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Non-small Cell Lung Cancer
Enrollment 605 participants
Start Date 2020-12-21
Primary Completion 2024-05-10 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-31